Cargando…

Facilitating rapid access to addiction treatment: a randomized controlled trial

BACKGROUND: Obtaining timely access to addiction medicine treatment for patients with substance use disorders is challenging and patients often have to navigate complex referral pathways. This randomized controlled trial examines the effect of providing an expedited pathway to addiction medicine tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Anita, Clarke, Sarah, Hardy, Kate, Kahan, Meldon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152083/
https://www.ncbi.nlm.nih.gov/pubmed/34034821
http://dx.doi.org/10.1186/s13722-021-00240-y
_version_ 1783698534655066112
author Srivastava, Anita
Clarke, Sarah
Hardy, Kate
Kahan, Meldon
author_facet Srivastava, Anita
Clarke, Sarah
Hardy, Kate
Kahan, Meldon
author_sort Srivastava, Anita
collection PubMed
description BACKGROUND: Obtaining timely access to addiction medicine treatment for patients with substance use disorders is challenging and patients often have to navigate complex referral pathways. This randomized controlled trial examines the effect of providing an expedited pathway to addiction medicine treatment on initial treatment engagement and health care utilization. METHODS: Individuals with possible alcohol or opioid use disorder were recruited from three residential withdrawal management services (WMS). Subjects randomized to the Delayed Intervention (DI) group were given contact information for a nearby addiction medicine clinic; those randomized to the Rapid Intervention (RI) group were given an appointment at the clinic within 2 days and were accompanied to their first appointment. RESULTS: Of the 174 individuals who were screened, 106 were randomized to either the DI or RI group. The two groups were similar in demographics, housing status, and substance use in the last 30 days. In the 6-month period following randomization, 85% of the RI group attended at least one clinic appointment, compared to only 29% in the DI group (p < 0.0001). The RI group had a mean of 6.39 ED visits per subject in the 12 months after randomization, while the DI group had a mean of 13.02 ED visits per subject in the same 12-month period (p = 0.0469). Other health utilization measures did not differ between the two groups. CONCLUSION: Providing immediate facilitated access to an addiction medicine service resulted in greater initial engagement and reduced emergency department visits at 6 months. Trial registration This trial is registered at the National Institutes of Health (ClinicalTrials.gov) under identifier #NCT01934751. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-021-00240-y.
format Online
Article
Text
id pubmed-8152083
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81520832021-05-26 Facilitating rapid access to addiction treatment: a randomized controlled trial Srivastava, Anita Clarke, Sarah Hardy, Kate Kahan, Meldon Addict Sci Clin Pract Research BACKGROUND: Obtaining timely access to addiction medicine treatment for patients with substance use disorders is challenging and patients often have to navigate complex referral pathways. This randomized controlled trial examines the effect of providing an expedited pathway to addiction medicine treatment on initial treatment engagement and health care utilization. METHODS: Individuals with possible alcohol or opioid use disorder were recruited from three residential withdrawal management services (WMS). Subjects randomized to the Delayed Intervention (DI) group were given contact information for a nearby addiction medicine clinic; those randomized to the Rapid Intervention (RI) group were given an appointment at the clinic within 2 days and were accompanied to their first appointment. RESULTS: Of the 174 individuals who were screened, 106 were randomized to either the DI or RI group. The two groups were similar in demographics, housing status, and substance use in the last 30 days. In the 6-month period following randomization, 85% of the RI group attended at least one clinic appointment, compared to only 29% in the DI group (p < 0.0001). The RI group had a mean of 6.39 ED visits per subject in the 12 months after randomization, while the DI group had a mean of 13.02 ED visits per subject in the same 12-month period (p = 0.0469). Other health utilization measures did not differ between the two groups. CONCLUSION: Providing immediate facilitated access to an addiction medicine service resulted in greater initial engagement and reduced emergency department visits at 6 months. Trial registration This trial is registered at the National Institutes of Health (ClinicalTrials.gov) under identifier #NCT01934751. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-021-00240-y. BioMed Central 2021-05-25 2021 /pmc/articles/PMC8152083/ /pubmed/34034821 http://dx.doi.org/10.1186/s13722-021-00240-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Srivastava, Anita
Clarke, Sarah
Hardy, Kate
Kahan, Meldon
Facilitating rapid access to addiction treatment: a randomized controlled trial
title Facilitating rapid access to addiction treatment: a randomized controlled trial
title_full Facilitating rapid access to addiction treatment: a randomized controlled trial
title_fullStr Facilitating rapid access to addiction treatment: a randomized controlled trial
title_full_unstemmed Facilitating rapid access to addiction treatment: a randomized controlled trial
title_short Facilitating rapid access to addiction treatment: a randomized controlled trial
title_sort facilitating rapid access to addiction treatment: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152083/
https://www.ncbi.nlm.nih.gov/pubmed/34034821
http://dx.doi.org/10.1186/s13722-021-00240-y
work_keys_str_mv AT srivastavaanita facilitatingrapidaccesstoaddictiontreatmentarandomizedcontrolledtrial
AT clarkesarah facilitatingrapidaccesstoaddictiontreatmentarandomizedcontrolledtrial
AT hardykate facilitatingrapidaccesstoaddictiontreatmentarandomizedcontrolledtrial
AT kahanmeldon facilitatingrapidaccesstoaddictiontreatmentarandomizedcontrolledtrial